Literature DB >> 16757608

Assessment of two commercial susceptibility test methods for determination of daptomycin MICs.

James H Jorgensen1, Sharon A Crawford.   

Abstract

Daptomycin is a lipopeptide antibiotic with activity against several important gram-positive bacterial pathogens, including drug-resistant staphylococci and enterococci. Because the mechanism of action of daptomycin is calcium-dependent depolarization of the cell membrane, susceptibility testing requires medium supplemented with a physiological level of calcium. This study assessed two Food and Drug Administration-cleared commercial test devices for determination of daptomycin MICs, Etest and JustOne. A collection of 220 selected isolates, including Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, E. faecium, E. avium, E. durans, E. casseliflavus, and E. gallinarum, were tested by both methods. Included in the collection were 22 S. aureus and 14 Enterococcus sp. isolates that were recovered from patients and were nonsusceptible on the basis of the daptomycin MICs. As the reference method for comparison, all isolates were tested by the Clinical and Laboratory Standards Institute broth microdilution method incorporating cation-adjusted Mueller-Hinton broth with 50 microg/ml calcium. Daptomycin MICs agreed, within 1 twofold dilution, for 97% of the isolates by Etest and for 100% by JustOne. However, daptomycin MICs determined by Etest were 1 dilution lower than the reference MICs for 65% of the Enterococcus sp. isolates tested. This resulted in 28.5% very major (VM) errors (4/14) with enterococci (all E. faecium) but none (0/22) with staphylococci. Use of JustOne yielded MICs that were 1 dilution lower than the reference MICs for 69% of the staphylococci and 25% of the enterococci. This resulted in 13.6% VM errors (3/22) with staphylococci and 14.3% VM errors (2/14) with enterococci. The manufacturer-recommended JustOne inoculum preparation resulted in mean colony counts of only 5 x 10(4) to 1 x 10(5) CFU/ml in the wells of the strip. Increasing the inoculum to 3 x 10(5) to 4 x 10(5) CFU/ml eliminated two of five VM errors upon retesting. No major interpretive errors occurred with either device. In summary, daptomycin MICs generated by the Etest or JustOne method generally agreed within 1 dilution of the reference daptomycin MICs. However, both devices produced slightly lower MICs that resulted in some VM errors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16757608      PMCID: PMC1489422          DOI: 10.1128/JCM.00076-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

1.  In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers.

Authors:  A L Barry; P C Fuchs; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Resistance studies with daptomycin.

Authors:  J A Silverman; N Oliver; T Andrew; T Li
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy.

Authors:  James S Lewis; Aaron Owens; Jose Cadena; Kathryn Sabol; Jan E Patterson; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

4.  Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Authors:  R L Akins; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

5.  Daptomycin disrupts membrane potential in growing Staphylococcus aureus.

Authors:  W E Alborn; N E Allen; D A Preston
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

6.  Fluorescence indicates a calcium-dependent interaction between the lipopeptide antibiotic LY146032 and phospholipid membranes.

Authors:  J H Lakey; M Ptak
Journal:  Biochemistry       Date:  1988-06-28       Impact factor: 3.162

7.  In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.

Authors:  Laura A Jevitt; Amanda J Smith; Portia P Williams; Patti M Raney; John E McGowan; Fred C Tenover
Journal:  Microb Drug Resist       Date:  2003       Impact factor: 3.431

8.  Calcium-supplemented daptomycin Etest strips for susceptibility testing on Iso-Sensitest agar.

Authors:  Alan P Johnson; Shazad Mushtaq; Marina Warner; David M Livermore
Journal:  J Antimicrob Chemother       Date:  2004-03-31       Impact factor: 5.790

9.  In vitro activity of daptomycin against vancomycin-resistant enterococci of various Van types and comparison of susceptibility testing methods.

Authors:  James H Jorgensen; Sharon A Crawford; Cynthia C Kelly; Jan E Patterson
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

10.  The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.

Authors:  Robert D Arbeit; Dennis Maki; Francis P Tally; Edward Campanaro; Barry I Eisenstein
Journal:  Clin Infect Dis       Date:  2004-05-20       Impact factor: 9.079

View more
  6 in total

1.  Multicenter evaluation of the Etest and disk diffusion methods for differentiating daptomycin-susceptible from non-daptomycin-susceptible Staphylococcus aureus isolates.

Authors:  Laura A Jevitt; Grace M Thorne; Maria M Traczewski; Ronald N Jones; John E McGowan; Fred C Tenover; Steven D Brown
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

2.  Activity of daptomycin against Listeria monocytogenes isolates from cerebrospinal fluid.

Authors:  Lodewijk Spanjaard; Christina M J E Vandenbroucke-Grauls
Journal:  Antimicrob Agents Chemother       Date:  2008-02-19       Impact factor: 5.191

3.  Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype.

Authors:  Ilana Lopes Baratella da Cunha Camargo; Hui-Min Neoh; Longzhu Cui; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2008-09-29       Impact factor: 5.191

4.  In vitro activity of daptomycin against Staphylococci isolated from bacteremia and community-onset skin and soft tissue infections in France: data from two nationwide studies.

Authors:  O Gallon; C Guillet-Caruba; B Lamy; F Laurent; F Doucet-Populaire; J-W Decousser
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-06-06       Impact factor: 3.267

5.  Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.

Authors:  Stefanie Henken; Jennifer Bohling; Jens Martens-Lobenhoffer; James C Paton; A David Ogunniyi; David E Briles; Vyvyan C Salisbury; Dirk Wedekind; Stefanie M Bode-Böger; Thomas Welsh; Franz C Bange; Tobias Welte; Ulrich A Maus
Journal:  Antimicrob Agents Chemother       Date:  2009-11-16       Impact factor: 5.191

6.  Case-control study comparing de novo and daptomycin-exposed daptomycin-nonsusceptible Enterococcus infections.

Authors:  Theodoros Kelesidis; Angela L P Chow; Romney Humphries; Daniel Z Uslan; David Pegues
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.938

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.